$4.78
0.83% day before yesterday
Nasdaq, Jul 11, 10:00 pm CET
ISIN
US0390142042
Symbol
RKDA

Arcadia Biosciences, Inc. Target price 2025 - Analyst rating & recommendation

Arcadia Biosciences, Inc. Classifications & Recommendation:

Buy
86%
Hold
14%

Arcadia Biosciences, Inc. Price Target

Target Price $12.24
Price $4.78
Potential
Number of Estimates 3
3 Analysts have issued a price target Arcadia Biosciences, Inc. 2026 . The average Arcadia Biosciences, Inc. target price is $12.24. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 7 analysts: 6 Analysts recommend Arcadia Biosciences, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Arcadia Biosciences, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Arcadia Biosciences, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 5.05 6.53
13.48% 29.27%
EBITDA Margin -145.54% -39.33%
22.43% 72.98%
Net Margin -139.41% -1.28%
55.63% 99.08%

3 Analysts have issued a sales forecast Arcadia Biosciences, Inc. 2025 . The average Arcadia Biosciences, Inc. sales estimate is

$6.5m
Unlock
. This is
24.11% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$6.7m 27.76%
Unlock
, the lowest is
$6.3m 19.24%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $5.1m 13.48%
2025
$6.5m 29.27%
Unlock
2026
$8.2m 25.00%
Unlock

3 Analysts have issued an Arcadia Biosciences, Inc. EBITDA forecast 2025. The average Arcadia Biosciences, Inc. EBITDA estimate is

$-2.6m
Unlock
. This is
57.57% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-2.6m 56.32%
Unlock
, the lowest is
$-2.5m 59.23%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-7.4m 38.94%
2025
$-2.6m 65.07%
Unlock
2026
$-3.7m 45.02%
Unlock

EBITDA Margin

2024 -145.54% 22.43%
2025
-39.33% 72.98%
Unlock
2026
-45.63% 16.02%
Unlock

3 Arcadia Biosciences, Inc. Analysts have issued a net profit forecast 2025. The average Arcadia Biosciences, Inc. net profit estimate is

$-80.0k
Unlock
. This is
96.04% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-80.0k 96.04%
Unlock
, the lowest is
$-90.0k 95.54%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-7.0m 49.64%
2025
$-80.0k 98.86%
Unlock
2026
$-3.3m 4,000.00%
Unlock

Net Margin

2024 -139.41% 55.63%
2025
-1.28% 99.08%
Unlock
2026
-40.24% 3,043.75%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -5.16 -0.06
54.34% 98.84%
P/E negative
EV/Sales 0.52

3 Analysts have issued a Arcadia Biosciences, Inc. forecast for earnings per share. The average Arcadia Biosciences, Inc. EPS is

$-0.06
Unlock
. This is
95.92% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.06 95.92%
Unlock
, the lowest is
$-0.06 95.92%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-5.16 54.34%
2025
$-0.06 98.84%
Unlock
2026
$-2.40 3,900.00%
Unlock

P/E ratio

Current -3.25 435.26%
2025
-78.10 2,301.82%
Unlock
2026
-1.99 97.45%
Unlock

Based on analysts' sales estimates for 2025, the Arcadia Biosciences, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.64 181.01%
2025
0.52 19.34%
Unlock
2026
0.41 19.99%
Unlock

P/S ratio

Current 1.24 52.77%
2025
1.00 19.48%
Unlock
2026
0.80 20.00%
Unlock

Current Arcadia Biosciences, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Aug 21 2024
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 21 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today